Evidence map›Paper›PMID 24809459›Full record

ArticlePLoS pathogens2014

Phosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosis.

Catherine Vilchèze, Virginie Molle, Séverine Carrère-Kremer, Jade Leiba, Lionel Mourey, Shubhada Shenai, Grégory Baronian, Joann Tufariello, Travis Hartman, Romain Veyron-Churlet and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 76 citations in OpenAlex.

  1. Protein kinase F regulates the virulence ofInfection and immunity · 2026
    Article
  2. Article
  3. Review
  4. Protein kinase F regulates the virulence ofbioRxiv : the preprint server for biology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Drug-TolerantInternational journal of molecular sciences · 2023
    Article
  10. Article
  11. Article
  12. iScience · 2023
    Article
  13. Anti-tuberculosis drug developmentFrontiers in microbiology · 2022
    Review
  14. Phenotypic adaptation ofFrontiers in cellular and infection microbiology · 2022
    Review
  15. Mycobacterial fatty acid catabolism is repressed by FdmR to sustain lipogenesis and virulence.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  16. Article
  17. Article
  18. Frontiers in microbiology · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Catherine VilchèzeHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, New York, United States of America.
Virginie MolleLaboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Universités de Montpellier II et I, CNRS; UMR 5235, Montpellier, France.
Séverine Carrère-KremerLaboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Universités de Montpellier II et I, CNRS; UMR 5235, Montpellier, France.
Jade LeibaLaboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Universités de Montpellier II et I, CNRS; UMR 5235, Montpellier, France.
Lionel MoureyInstitut de Pharmacologie et de Biologie Structurale, CNRS, Toulouse, France; The Université de Toulouse, Université Paul Sabatier, IPBS, Toulouse, France.
Shubhada ShenaiDivision of Infectious Diseases, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey, United States of America.
Grégory BaronianLaboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Universités de Montpellier II et I, CNRS; UMR 5235, Montpellier, France.
Joann TufarielloHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, New York, United States of America.
Travis HartmanHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, New York, United States of America.
Romain Veyron-ChurletLaboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Universités de Montpellier II et I, CNRS; UMR 5235, Montpellier, France.
Xavier TrivelliUniversité Lille 1, Unité de Glycobiologie Structurale et Fonctionnelle, UGSF, Villeneuve d'Ascq, France; CNRS, UMR 8576, Villeneuve d'Ascq, France.
Sangeeta TiwariHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, New York, United States of America.
Brian WeinrickHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, New York, United States of America.
David AllandDivision of Infectious Diseases, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey, United States of America.
Yann GuérardelUniversité Lille 1, Unité de Glycobiologie Structurale et Fonctionnelle, UGSF, Villeneuve d'Ascq, France; CNRS, UMR 8576, Villeneuve d'Ascq, France.
William R JacobsHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, New York, United States of America.
Laurent KremerLaboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Universités de Montpellier II et I, CNRS; UMR 5235, Montpellier, France; INSERM, DIMNP, Montpellier, France.
Centre National de la Recherche Scientifique · FRAlbert Einstein College of Medicine · USHoward Hughes Medical Institute · USLaboratory of Pathogens and Host Immunity · FRRutgers Health · USRutgers, The State University of New Jersey · USUniversité Fédérale de Toulouse Midi-Pyrénées · FR

Funding

Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI GOLDSTEIN, HARRIS · 2003 to 2013
$18.6M
"The Tuberculous Granuloma"P01AI063537 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI PORCELLI, STEVEN A · 2005 to 2015
$15.7M
Molecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7M
MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR01AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 2022
$7.1M
Vaccines for Extensively Drug Resistant TuberculosisR01AI098925 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JACOBS, WILLIAM ROBERT · 2012 to 2016
$5.8M
MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR22AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 1991
–
Howard Hughes Medical InstituteNIAID NIH HHS AI-051519NIAID NIH HHS AI26170NIAID NIH HHS P01 AI063537NIAID NIH HHS P30 AI051519NIAID NIH HHS R01 AI026170NIAID NIH HHS R01 AI098925NIAID NIH HHS R37 AI026170
6 · The paper itself

Abstract

Mycobacterium tuberculosis bacilli display two signature features: acid-fast staining and the capacity to induce long-term latent infections in humans. However, the mechanisms governing these two important processes remain largely unknown. Ser/Thr phosphorylation has recently emerged as an important regulatory mechanism allowing mycobacteria to adapt their cell wall structure/composition in response to their environment. Herein, we evaluated whether phosphorylation of KasB, a crucial mycolic acid biosynthetic enzyme, could modulate acid-fast staining and virulence. Tandem mass spectrometry and site-directed mutagenesis revealed that phosphorylation of KasB occurred at Thr334 and Thr336 both in vitro and in mycobacteria. Isogenic strains of M. tuberculosis with either a deletion of the kasB gene or a kasB_T334D/T336D allele, mimicking constitutive phosphorylation of KasB, were constructed by specialized linkage transduction. Biochemical and structural analyses comparing these mutants to the parental strain revealed that both mutant strains had mycolic acids that were shortened by 4-6 carbon atoms and lacked trans-cyclopropanation. Together, these results suggested that in M. tuberculosis, phosphorylation profoundly decreases the condensing activity of KasB. Structural/modeling analyses reveal that Thr334 and Thr336 are located in the vicinity of the catalytic triad, which indicates that phosphorylation of these amino acids would result in loss of enzyme activity. Importantly, the kasB_T334D/T336D phosphomimetic and deletion alleles, in contrast to the kasB_T334A/T336A phosphoablative allele, completely lost acid-fast staining. Moreover, assessing the virulence of these strains indicated that the KasB phosphomimetic mutant was attenuated in both immunodeficient and immunocompetent mice following aerosol infection. This attenuation was characterized by the absence of lung pathology. Overall, these results highlight for the first time the role of Ser/Thr kinase-dependent KasB phosphorylation in regulating the later stages of mycolic acid elongation, with important consequences in terms of acid-fast staining and pathogenicity.

Indexed as

3-Oxoacyl-(Acyl-Carrier-Protein) SynthaseAnimalsBacterial ProteinsCatalytic DomainCell WallLipid MetabolismMiceMice, Inbred C57BLMice, SCIDMicrobiological TechniquesModels, MolecularMycobacterium tuberculosisMycolic AcidsPhosphorylationProtein Serine-Threonine KinasesStaining and Labeling3-Oxoacyl-(Acyl-Carrier-Protein) SynthaseBacterial ProteinsKasB protein, Mycobacterium tuberculosisMycolic AcidsProtein Serine-Threonine Kinases

Identifiers

PMID24809459
PMCPMC4014462
OpenAlexW2025963602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.